Long-term efficacy and safety of dupilumab in patients enrolled from Latin American centers from the open-label extension LIBERTY ASTHMA TRAVERSE study.
Abraham Alí Munive, Marco Antonio Fernández Corzo, Adrián Rendón et al.
✦ AI-curated · Sources linked
In 30 seconds
This post hoc analysis of the open-label extension TRAVERSE study examined long-term dupilumab outcomes in patients with moderate-to-severe asthma enrolled at Latin American centers after completing a phase 2b or phase 3 QUEST study. Among 596 patients, safety was consistent with dupilumab’s known profile. Severe exacerbation rates remained low (0.115-0.459 annually), and pre-bronchodilator FEV1 improvements were sustained to Week 96, with mean changes from parent-study baseline of 0.28-0.35 L. Improvements in asthma control and quality of life were observed through Week 48, the last assessment for those outcomes.
Key findings
- The annualized rate of severe asthma exacerbations remained low across patients (0.115-0.459).
- Pre-bronchodilator FEV1 improvements were sustained to Week 96, with mean changes from parent-study baseline of 0.28-0.35 L.
- ACQ-5 and AQLQ improvements were observed to Week 48, their last assessed time-point; type 2 biomarkers decreased over time.
- Safety was consistent with the known dupilumab safety profile.
Why it matters
The findings add long-term evidence from Latin American patients with moderate-to-severe asthma, a population identified by the authors as having a substantial burden of uncontrolled disease. Sustained lung-function improvement and low exacerbation rates, alongside a safety profile consistent with prior experience, help characterize outcomes during extended dupilumab treatment in this regional population.
What to keep in mind
This was a post hoc analysis of an open-label extension, not a randomized comparison during the extension. ACQ-5 and AQLQ were assessed only through Week 48.